B Lymphocyte Chemoattractant Simoa (BLC Simoa)

B lymphocyte chemoattractant [BLC, CXCL13, B-cell-attracting chemokine-1 (BAC-1)] belongs to the CXC chemokine family and is expressed in the liver, follicles of the spleen, lymph nodes, and Peyer’s patches by T follicular helper cells, dendritic cells, osteoclasts, and macrophages. BLC induces B cell chemotaxis by binding to the chemokine receptor, CXCR5. CXCL13/CXCR5 signaling also promotes progression and lymph node metastases of oral squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, neuroblastoma, leukemias, multiple myelomas, lymphomas, breast cancers, colorectal cancers, lung cancers, and prostate cancers. T cell-mediated rejection of kidney allografts has been linked to B cell clustering and more severe disease. CXCL13 serum levels have been identified as a potential biomarker for B cell clustering and was correlated with more severe disease. RBM's Simoa BLC assay may be an important analytical tool for clinical studies of diseases involving B cell dysfunction.

Swiss-Prot Accession Number: O43927

Product Associations Product Associations

This analyte is not currently part of Myriad RBM's testing menu.

Myriad RBM Publications Publications
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial (2020) Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Boothsma H Annals of the Rheumatic Disease
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study. (2019) Schafer PH, Kivitz AJ, Ma J, Korish S, Sutherland D, Li L, Azaryan A, Kosek J, Adams M, Capone L, Hur EM, Hough DR, Ringheim GE Rheumatology and Therapy